Home › Compound Library › Sermorelin
Growth hormone axis
Sermorelin: The GHRH Fragment That Was Once an Approved Drug
The short answer
Sermorelin is the first 29 amino acids of GHRH, the body’s own signal to release growth hormone. It was approved in the US as Geref and withdrawn from the market in 2008 for commercial reasons rather than safety, and it is now supplied through compounding pharmacies.
Questions people ask about Sermorelin
- What is sermorelin?
- Is sermorelin FDA approved?
- Why was sermorelin discontinued?
- Sermorelin vs CJC-1295: what is the difference?
- Sermorelin vs ipamorelin: what is the difference?
- Does sermorelin build muscle?
- Does sermorelin help with sleep?
- What are sermorelin’s side effects?
- Is sermorelin banned in sport?
Sermorelin at a glance
| Also called | GHRH (1-29); Geref (discontinued brand); sermorelin acetate |
|---|---|
| What it is | A 29-amino-acid fragment of growth hormone-releasing hormone |
| Acts on | The GHRH receptor in the pituitary |
| Main system | Growth hormone axis: body composition, recovery, sleep |
| Evidence level | Was an approved medicine with clinical data; little modern trial work for the uses it is now sold for |
| FDA status (Sept 2026) | No approved product. Geref was withdrawn in 2008; compounding pharmacies are the route it comes through |
| In sport | Prohibited at all times (WADA S2, growth hormone releasing factors) |
What is sermorelin?
GHRH is a 44-amino-acid hormone made in the hypothalamus. Its job is to tell the pituitary to release growth hormone. Researchers established decades ago that the biological activity lives in the first 29 amino acids, and sermorelin is that fragment.
It has an unusual history for a peptide in this library. It was an approved prescription medicine in the US, sold as Geref and used in the diagnosis and treatment of growth hormone deficiency in children. The manufacturer withdrew it from the US market in 2008 as a commercial decision, not because of a safety or efficacy finding.
Targeted Peptide Systems profiles it at pp. 183–185, Metabolic Precision at pp. 118–121, and The Longevity Map at pp. 80–81.
How does sermorelin work?
Growth hormone is released in pulses, mostly during the first hours of deep sleep, under two opposing signals: GHRH opens the tap and somatostatin closes it.
Sermorelin binds the GHRH receptor and asks for a pulse. What it does not do is supply growth hormone from outside, which is the distinction that matters:
- The pituitary is still the source, so the pulse pattern and the feedback loops that limit it stay intact.
- Its effect fades within about half an hour, which is why it mirrors a natural pulse more closely than the long-acting analogs do.
- Somatostatin still applies the brake, so the system retains its own ceiling.
Metabolic Precision (pp. 240–241) gives the pairing rule for this class: one GHRH analog, optionally with one ghrelin-receptor compound. Two GHRH analogs together compete for the same receptor and gain nothing.
What does the research show?
The approved era. Sermorelin’s clinical record was built for a specific job: testing and treating growth hormone deficiency in children. It did that well enough to be approved, and the safety profile from that period is the most solid thing about it.
Where the evidence stands. Sermorelin’s approval-era record is solid for the job it was built to do. A modern trial for the reasons it is mostly sold today — body composition, recovery, sleep quality and the general territory of ageing well — is still to be run. A 2026 review in Sports Med went through the approved and unapproved peptides used for musculoskeletal injury and athletic performance and found the same pattern across this class: plausible mechanism, thin outcome data (reference 1).
What that means in practice. The mechanism is not in question. GHRH raises growth hormone; that has been measured many times. The open question is what a raised pulse produces over months in an adult who is not growth hormone deficient, and that question has not been answered by trial.
Side effects and cautions
The effects usually listed for this class belong to growth hormone itself, and that record comes largely from growth hormone given from outside the body at exposures above the range a body would produce on its own: fluid retention, tingling in the hands, joint aches, headache, and reduced insulin sensitivity in the short term. Injection-site reactions belong to the injection rather than the hormone, and are the most commonly reported effect for sermorelin specifically.
Sermorelin prompts your own pituitary pulse instead, under the feedback that normally limits it, so the physiological range is where the mechanism sits. Push past that range and the effects above become possibilities rather than a given, which is why blood sugar is worth following and why monitoring belongs in the plan from the start.
Metabolic Precision (p. 73) adds the point most protocols miss: the growth hormone axis responds poorly in an insulin-resistant, high-visceral-fat state, because that state suppresses the response in the first place. Correcting metabolism first is the book’s rule.
Not for anyone with active cancer, uncontrolled diabetes or pituitary disease outside medical care.
Is sermorelin legal or FDA approved?
There is no approved sermorelin product in the US today. Geref was approved and then withdrawn from the market in 2008, a commercial decision rather than a safety one. Since then it has reached patients through compounding pharmacies on a prescription.
It was not part of the July 2026 review. The FDA advisory committee that recommended six peptides that month did not take up sermorelin (references 2, 3).
Banned in sport. Growth hormone releasing factors are prohibited at all times under the World Anti-Doping Agency list, in and out of competition (reference 4).
Status changes. This page is reviewed and updated as it does.
Sermorelin vs CJC-1295, tesamorelin and ipamorelin
All four touch the growth hormone axis, and the difference is which door they use and how long they hold it open.
- Sermorelin is the short-acting GHRH analog. Its pulse comes and goes quickly, closest to the natural rhythm.
- CJC-1295 is the same signal engineered to last, which raises growth hormone and IGF-1 for far longer. That is either the point or the drawback, depending on whether you want the natural pattern preserved.
- Tesamorelin is the stabilised GHRH analog that went through Phase 3 and is an approved medicine for one specific population.
- Ipamorelin is not a GHRH analog at all. It works through the ghrelin receptor, which is why the mechanism points to it complementing a GHRH analog rather than competing with one.
That last point is mechanism, not a protocol suggestion. Metabolic Precision (pp. 240–241) is where the book works through the choice.
Risk, benefit, and the conversation this page is for
How to weigh it. Some research peptides have a quiet toxicology record, or an unfinished efficacy record. sermorelin is a different case: on its mechanism it genuinely moves physiology, in this case growth hormone and IGF-1, and that is the reason to weigh it with due diligence rather than enthusiasm. Monitoring is paramount here, and the markers that matter are blood sugar, fluid balance, and IGF-1 itself for anyone with a cancer history.
The regulatory picture is moving, selectively. In July 2026 an FDA advisory committee recommended six peptides, BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax, for the list of bulk substances compounding pharmacies may use. Sermorelin was not among them, and it did not need to be in the same way: it was an approved medicine until 2008, withdrawn for commercial reasons rather than safety, and compounding pharmacies are the route it comes through today. Reading those decisions one at a time is more useful than treating every compound outside the approved list as equivalent.
Why the class is taken seriously. It carries something unusual for a compound in this library: a period of regulatory approval, and the safety record that came with it. That history is the most solid thing about it, and it is why the class is taken seriously. The useful question is not whether engaging it does anything. It is whether you have done the due diligence to make an informed decision about engaging it at all: what your baseline looks like, what else you are taking, what you would measure along the way, and what would tell you to stop.
Which is the point of the series. Nothing here is a recommendation to use sermorelin. People misuse approved medicines and unapproved compounds alike, and that is neither the purpose nor the intent of this page. The point is a better conversation than the internet usually allows: with a clinician who knows your history, your labs and everything else you take, and who can help build a plan that fits you.
Sermorelin: frequently asked questions
What is sermorelin?
A 29-amino-acid fragment of GHRH, the body’s own signal for growth hormone release. It acts on the GHRH receptor in the pituitary.
Is sermorelin FDA approved?
Not currently. It was approved as Geref and withdrawn from the US market in 2008 for commercial reasons rather than safety, and it now reaches patients through compounding pharmacies.
Why was sermorelin discontinued?
The manufacturer withdrew it as a business decision. It was not pulled over a safety or efficacy finding, which is why it is still prescribed as a compounded preparation.
Sermorelin vs CJC-1295: what is the difference?
Both work on the GHRH receptor. Sermorelin acts and clears quickly, closer to a natural pulse; CJC-1295 is engineered to last much longer. Using both together would be two compounds competing for one receptor.
Sermorelin vs ipamorelin: what is the difference?
Different receptors. Sermorelin is a GHRH analog; ipamorelin works through the ghrelin receptor. On mechanism they complement each other rather than compete, which is why the two classes are discussed as a pair.
Does sermorelin build muscle?
The reasoning runs through growth hormone, which supports lean mass. How much of that shows up in a given person depends on their own metabolic environment, and Metabolic Precision (p. 73) puts correcting metabolism before adding a growth hormone compound.
Does sermorelin help with sleep?
Growth hormone release and deep sleep are linked, and Metabolic Precision (p. 72) describes improved slow-wave sleep as one effect of growth hormone axis support.
What are sermorelin’s side effects?
Injection-site reactions are the most commonly reported. The wider list belongs to growth hormone itself and is documented mostly from growth hormone given from outside the body at levels above the body’s own range, so those read as possibilities if levels are pushed past the physiological range.
Is sermorelin banned in sport?
Yes. Growth hormone releasing factors are prohibited at all times under WADA’s S2 category.
Where Sermorelin appears in our books
This page is the plain-language overview. The books go further: mechanism detail, evidence tiers, how Sermorelin fits a full protocol, and the cautions that go with it. Page numbers refer to the print editions.
Targeted Peptide Systems
Profile, growth hormone secretagogues · pp. 183-185
About the bookLook Inside
Books marked Look Inside include these exact pages in their free preview.
Related compounds
See how Sermorelin fits a protocol
The free Protocol Builder maps the pathways a compound works on and shows what complements it for your goal, built from the same database as this library.
Open the Protocol BuilderSee the book seriesReferences
- Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. 2026;56(8):1921–1935. View source
- U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. View source
- National Community Pharmacists Association. FDA advisory committee nominates six peptides for pharmacies to compound. July 31, 2026. View source
- World Anti-Doping Agency. The 2026 Prohibited List. View source
How this page is maintained. Regulatory status and trial results change. We review this page against current sources and update it as new information becomes available; the date at the top shows the last review.
Educational information only, not medical advice. Sermorelin is discussed here for education. Nothing on this page is a recommendation to use it or a dosing guide. Talk to a qualified clinician before starting, stopping or combining any compound.